- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03707899
The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers Volunteers
August 27, 2019 updated by: Jeil Pharmaceutical Co., Ltd.
An Open Label, Randomized, Single-dose, 4-period Cross-over Study to Compare the Pharmacokinetics and Safety Following Administration of JLP-1401 and Co-administration of Telmisartan/Amlodipine and Rosuvastatin in Healthy Adult Volunteers
The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
49
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Jeonju, Korea, Republic of
- Chonbuk National University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male volunteer, age is over 19 years Body weight is over 55kg, The result of Body Mass Index(BMI) is not less than 17.5 kg/m2 , no more than 30.5 kg/m2
- Subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial
- Subject who has the ability and willingness to participate the whole period of trial
Exclusion Criteria:
- Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in kidney, liver, cardiovascular system, respiratory system, endocrine system, or neuropsychiatric system.
- Subjects who are allergic to investigational drug.
- Subjects who have a medical history which can affect the clinical trial.
- SBP < 90 mmHG, SBP > 140mmHG or DBP < 60 mmHG, DBP > 100mmHg
- AST or ALT > X 2 UNL
- CK > X 2 UNL
- History of drug abuse or positive drug screening.
- Participation in other drug studies within 3 months prior to the drug administration.
- Whole blood donation within 60 days, blood component donation within 30 days or who got transfusion within 30days.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group I (JLP-1401)
JLP-1401(Telmisartan 80 mg, amlodipine 5 mg, rosuvastatin 5 mg)
|
Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
|
ACTIVE_COMPARATOR: Group II (Telmisartan/Amlodipine, Rosuvastatin)
Twinsta(Telmisartan 80 mg, amlodipine 5 mg) and Crestor(rosuvastatin 5 mg)
|
Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCt
Time Frame: 72 hr after baseline
|
Area under the curve of telmisartan, amlodipine, rosuvastatin at 72 hours after baseline
|
72 hr after baseline
|
Cmax
Time Frame: 72 hr after baseline
|
Peak concentration of telmisartan, amlodipine, rosuvastatin at 72 hours after baseline
|
72 hr after baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 13, 2018
Primary Completion (ACTUAL)
February 18, 2019
Study Completion (ACTUAL)
May 22, 2019
Study Registration Dates
First Submitted
October 14, 2018
First Submitted That Met QC Criteria
October 14, 2018
First Posted (ACTUAL)
October 16, 2018
Study Record Updates
Last Update Posted (ACTUAL)
August 29, 2019
Last Update Submitted That Met QC Criteria
August 27, 2019
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Lipid Metabolism Disorders
- Dyslipidemias
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Amlodipine
- Rosuvastatin Calcium
- Telmisartan
- Telmisartan amlodipine combination
Other Study ID Numbers
- JLP-1401-102-PK
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension With Dyslipidemia
-
Jeil Pharmaceutical Co., Ltd.CompletedDyslipidemia With HypertensionKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemia Patients With HypertensionKorea, Republic of
-
Jeil Pharmaceutical Co., Ltd.CompletedHypertension With DyslipidemiaKorea, Republic of
-
TakedaWithdrawnEssential Hypertension With Stable Angina and DyslipidemiaJapan
-
University of Campinas, BrazilCompletedDiabetes Mellitus, Type 2 | Dyslipidemia Associated With Type II Diabetes Mellitus | Hypertension ArterialBrazil
-
Hospital Universitario Reina Sofia de CordobaSpanish Society of Family and Community MedicineCompletedPatients With DyslipidemiaSpain
-
AstraZenecaCompletedPatients With DyslipidemiaBrazil
-
Boryung Pharmaceutical Co., LtdCompleted
-
Chong Kun Dang PharmaceuticalCompletedHypertensive Patients With DyslipidemiaKorea, Republic of
-
Boryung Pharmaceutical Co., LtdCompletedEssential Hypertension, DyslipidemiaKorea, Republic of
Clinical Trials on JLP-1401
-
Jeil Pharmaceutical Co., Ltd.CompletedOveractive Bladder | Benign Prostatic Hyperplasia | LUTS
-
Jeil Pharmaceutical Co., Ltd.CompletedOveractive BladderKorea, Republic of
-
Immunovant Sciences GmbHRecruitingGraves DiseaseGermany
-
Jeil Pharmaceutical Co., Ltd.CompletedOveractive Bladder(OAB)Korea, Republic of
-
Immunovant Sciences GmbHTerminatedWarm Autoimmune Hemolytic AnemiaUnited States, Korea, Republic of, Israel, United Kingdom, Spain, Thailand
-
Bristol-Myers SquibbCompletedHodgkin's LymphomasUnited States
-
Immunovant Sciences GmbHCompleted
-
Takara Bio Inc.Completed
-
Anterios Inc.Completed
-
BioFirst CorporationCompleted